BR112012030818A2 - "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" - Google Patents

"derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"

Info

Publication number
BR112012030818A2
BR112012030818A2 BR112012030818A BR112012030818A BR112012030818A2 BR 112012030818 A2 BR112012030818 A2 BR 112012030818A2 BR 112012030818 A BR112012030818 A BR 112012030818A BR 112012030818 A BR112012030818 A BR 112012030818A BR 112012030818 A2 BR112012030818 A2 BR 112012030818A2
Authority
BR
Brazil
Prior art keywords
inhibitors
modified
betulinic acid
acid derivatives
hiv maturation
Prior art date
Application number
BR112012030818A
Other languages
English (en)
Inventor
Regueiro-Ren Alicia
Swidorski Jacob
Liu Zheng
A. Meanwell Nicholas
Sit Sing-Yuen
Chen Jie
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112012030818A2 publication Critical patent/BR112012030818A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

derivados de ácido c-3 betulínico modificado inibidores da maturação do hiv. compostos tendo propriedades medicamentosas e que podem afetar biologia, suas composições farmacêuticas e métodos de uso são apresentados. em particular, ácido c-3 betulínico modificado e outros derivados de produtos naturais estruturalmente relacionados que possuem atividade antiviral ímpar são fornecidos como inibidores da maturação do hiv. esses compostos são úteis para o tratamento de hiv e aids.
BR112012030818A 2010-06-04 2011-06-02 "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" BR112012030818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35133810P 2010-06-04 2010-06-04
PCT/US2011/038879 WO2011153315A1 (en) 2010-06-04 2011-06-02 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (1)

Publication Number Publication Date
BR112012030818A2 true BR112012030818A2 (pt) 2019-09-24

Family

ID=44627236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030818A BR112012030818A2 (pt) 2010-06-04 2011-06-02 "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"

Country Status (12)

Country Link
US (1) US8754068B2 (pt)
EP (1) EP2576585B8 (pt)
JP (1) JP5752789B2 (pt)
CN (1) CN103038245B (pt)
AR (1) AR081637A1 (pt)
BR (1) BR112012030818A2 (pt)
CA (1) CA2801487C (pt)
EA (1) EA022393B1 (pt)
ES (1) ES2612452T3 (pt)
MX (1) MX2012013703A (pt)
TW (1) TW201201793A (pt)
WO (1) WO2011153315A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104688745B (zh) 2010-05-20 2019-11-12 爱荷华大学研究基金会 用于抑制肌萎缩的方法
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
JP6000283B2 (ja) * 2011-01-31 2016-09-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
EP3520793B1 (en) 2011-06-06 2023-03-29 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
ES2611727T3 (es) 2011-09-21 2017-05-10 VIIV Healthcare UK (No.5) Limited Derivados de ácido betulínico novedosos con actividad antivírica
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CN105102468A (zh) * 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
NZ724644A (en) 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
CN107250153A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 氧代羽扇豆烯衍生物
CA2967601A1 (en) * 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
BR112018001537A2 (pt) 2015-07-28 2018-09-18 Glaxosmithkline Ip No 2 Ltd composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratamento e para prevenção de uma infecção por hiv em um indivíduo, e, uso de um composto ou sal
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
US20180273579A1 (en) 2015-09-24 2018-09-27 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2018002849A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018002848A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
JP2019519571A (ja) 2016-06-30 2019-07-11 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製のアザ置換阻害剤
PT3784349T (pt) 2018-04-24 2024-01-22 Viiv Healthcare Uk No 5 Ltd Compostos com atividade inibidora de maturação do hiv
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
EP1068219B1 (en) * 1998-03-02 2006-12-20 The University of North Carolina at Chapel Hill Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040131629A1 (en) * 2002-09-26 2004-07-08 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
ES2319653T3 (es) * 2003-02-11 2009-05-11 Novelix Pharmaceuticals, Inc. Medicamento para la inhibicion del crecimiento de tumores.
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CA2560266A1 (en) * 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
JP2009527563A (ja) * 2006-02-21 2009-07-30 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス感染症を治療するのに有用な置換タラキサスタン
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2178376A4 (en) * 2007-08-03 2011-12-14 Advanced Life Sciences Inc LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
JP5588966B2 (ja) * 2008-04-18 2014-09-10 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７同族体化オレアノール酸誘導体
BR112012019762A2 (pt) * 2010-02-11 2016-02-23 Glaxosmithkline Llc composto, composição, e, método para tratar uma doença.

Also Published As

Publication number Publication date
CA2801487A1 (en) 2011-12-08
EA201270780A1 (ru) 2013-04-30
JP2013527242A (ja) 2013-06-27
EP2576585A1 (en) 2013-04-10
US8754068B2 (en) 2014-06-17
CA2801487C (en) 2017-12-05
ES2612452T3 (es) 2017-05-17
TW201201793A (en) 2012-01-16
CN103038245A (zh) 2013-04-10
CN103038245B (zh) 2015-03-25
US20120142707A1 (en) 2012-06-07
EP2576585B8 (en) 2016-12-21
JP5752789B2 (ja) 2015-07-22
AR081637A1 (es) 2012-10-10
EP2576585B1 (en) 2016-10-12
EA022393B1 (ru) 2015-12-30
MX2012013703A (es) 2012-12-17
WO2011153315A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
MX2013004491A (es) Boronatos como inhibidores de arginasa.
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
DOP2011000107A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
BR112017009852A2 (pt) composto, composição, e, usos de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.